Iovance Biotherapeutics, Inc.
IOVA
$3.83
-$0.07-1.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.05% | 3.02% | 11.43% | 16.52% | 16.18% |
| Total Depreciation and Amortization | -1.55% | 27.63% | 24.64% | 31.85% | 45.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.25% | 7.33% | 55.49% | 91.37% | 76.49% |
| Change in Net Operating Assets | 80.90% | 15.69% | -20.04% | -327.20% | -1,847.88% |
| Cash from Operations | 14.33% | 11.14% | 21.95% | 12.98% | 2.44% |
| Capital Expenditure | -205.68% | -175.01% | -71.76% | 36.97% | 50.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | 100.00% | 100.00% | 75.28% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 348.20% | 176.11% | 115.87% | 132.85% | -141.13% |
| Cash from Investing | 149.26% | 136.49% | 102.05% | 107.37% | 37.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -23.71% | -36.63% | -61.52% | -12.31% | -13.36% |
| Repurchase of Common Stock | 45.10% | 38.39% | -112.34% | -147.91% | -360.04% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -23.01% | -36.58% | -63.50% | -14.55% | -15.62% |
| Foreign Exchange rate Adjustments | 311.46% | -116.70% | 220.87% | 114.18% | 80.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.31% | 96.06% | -57.66% | 109.15% | -4.26% |